J&J said on Thursday it has reached a 10-year agreement with Tokyo-based contract drug developer Fujifilm Biotechnologies for ...

In a study known as CROWNS-2 published in JAMA, the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 ...

Drugmakers are investing more in U.S. manufacturing as President Donald Trump threatens tariffs, but facilities can take ...

The stock's fall snapped a two-day winning streak.

Patients with local or regional cutaneous squamous cell carcinoma are randomly assigned to receive cemiplimab or placebo post ...

The delays, first revealed in Regeneron’s Q2 report, were chalked up to manufacturing issues at Novo Nordisk-owned plants.

The hits just keep on coming for Regeneron’s Eylea franchise. | The FDA has extended its target action dates for two ...

Regeneron Pharmaceuticals ( NASDAQ: REGN) announced that the U.S. FDA has extended the target action dates for two regulatory ...

Before Novo arrived as its owner, issues at the Bloomington facility caused a two-month delay for Eylea HD’s FDA approval ...

Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...

Whether it’s a cook, a home health aide, or a direct support professional, domestic workers are critical for so many people ...

U.S. pharma bounced back in Q2, and in this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy ...